全球血漿療法市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計血漿療法市場將從 2025 年的 5.6 億美元成長到 2034 年的 19.2 億美元，2026 年至 2034 年的複合年成長率預計為 14.64%。

由於血漿療法在治療多種疾病和感染疾病具有潛在應用價值，全球血漿療法市場正備受關注。血漿療法是一種利用從康復患者或捐血者身上採集的血漿來提供抗體，從而幫助抵抗感染疾病的治療方法。目前，人們已探索將這種方法作為多種病毒性疾病爆發和免疫相關疾病的治療選擇。

多種因素正在推動血漿療法市場的發展。免疫學和血漿研究的進步加深了我們對抗體治療方法的理解。醫療機構和研究機構正在探索將血漿療法納入更廣泛的治療策略。研究經費的增加和全球合作也為該領域的臨床研究提供了支持。

隨著血漿療法在醫學應用領域的研究不斷深入，血漿療法市場預計將進一步發展。血漿採集和處理技術的進步將提高治療的可近性。隨著免疫療法和抗體療法的進步，基於血漿的治療方法可能在某些醫療治療中發揮輔助作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球血漿療法市場：按類型分類

• 市場分析、洞察與預測
• 純 PRP
• 富含白血球的PRP
• 純血小板濃縮纖維蛋白（PRF）
• 富含白血球的纖維蛋白（L-PRF）

第5章：全球血漿療法市場：依來源分類

• 市場分析、洞察與預測
• 自體
• 同種

第6章 全球血漿療法市場：依應用領域分類

• 市場分析、洞察與預測
• 整形外科
• 皮膚科
• 牙科
• 心肌損傷
• 神經損傷
• 其他

第7章 全球血漿療法市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院和診所
• 研究機構

第8章 全球血漿療法市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Biolife Plasma Services
  • Cambryn Biologics LLC
  • Biotest
  • CSL Ltd
  • Grifols International SA
  • Kedrion SPA
  • LFB SA
  • Bio Product Laboratory Ltd.（BPL）
  • China Biologic Products Inc
  • Octapharma

The Plasma Therapy Market size is expected to reach USD 1.92 Billion in 2034 from USD 0.56 Billion (2025) growing at a CAGR of 14.64% during 2026-2034.

The global plasma therapy market has gained attention due to its potential use in treating various medical conditions and infectious diseases. Plasma therapy involves using plasma obtained from recovered patients or donors to provide antibodies that help fight infections. This approach has been explored as a treatment option in several viral disease outbreaks and immune-related conditions.

Several factors are driving the development of the plasma therapy market. Advances in immunology and blood plasma research have improved understanding of antibody-based treatments. Healthcare institutions and research organizations are exploring plasma therapy as part of broader therapeutic strategies. Increased research funding and global collaboration have also supported clinical investigations in this field.

In the future, the plasma therapy market is expected to evolve as research continues to explore its medical applications. Improved plasma collection and processing technologies will enhance treatment availability. As medical science advances in immunotherapy and antibody treatments, plasma-based therapies may play a supporting role in certain healthcare treatments.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Pure PRP
• Leucocyte-rich PRP
• Pure Platelet-rich Fibrin (PRF)
• Leukocyte-rich Fibrin (L-PRF)

By Source

• Autologous
• Allogenic

By Application

• Orthopedics
• Dermatology
• Dental
• Cardiac Muscle Injury
• Nerve Injury
• Others

By End User

• Hospitals & Clinics
• Research Institutions

COMPANIES PROFILED

• Biolife Plasma Services, Cambryn Biologics LLC, Biotest, CSL Ltd, Grifols International SA, Kedrion SPA, LFB SA, Bio Product Laboratory Ltd BPL, China Biologic Products Inc, Octapharma
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PLASMA THERAPY MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Pure PRP Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Leucocyte-rich PRP Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Pure Platelet-rich Fibrin (PRF) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Leukocyte-rich Fibrin (L-PRF) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PLASMA THERAPY MARKET: BY SOURCE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Source
• 5.2. Autologous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Allogenic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PLASMA THERAPY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Orthopedics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Dental Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Cardiac Muscle Injury Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Nerve Injury Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PLASMA THERAPY MARKET: BY END USER 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End User
• 7.2. Hospitals & Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Research Institutions Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL PLASMA THERAPY MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type
  • 8.2.2 By Source
  • 8.2.3 By Application
  • 8.2.4 By End User
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type
  • 8.3.2 By Source
  • 8.3.3 By Application
  • 8.3.4 By End User
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type
  • 8.4.2 By Source
  • 8.4.3 By Application
  • 8.4.4 By End User
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type
  • 8.5.2 By Source
  • 8.5.3 By Application
  • 8.5.4 By End User
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type
  • 8.6.2 By Source
  • 8.6.3 By Application
  • 8.6.4 By End User
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL PLASMA THERAPY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Biolife Plasma Services
  • 10.2.2 Cambryn Biologics LLC
  • 10.2.3 Biotest
  • 10.2.4 CSL Ltd
  • 10.2.5 Grifols International S.A
  • 10.2.6 Kedrion S.P.A
  • 10.2.7 LFB SA
  • 10.2.8 Bio Product Laboratory Ltd. (BPL)
  • 10.2.9 China Biologic Products Inc
  • 10.2.10 Octapharma